Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 3/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.47 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9509924 | 0.84 | PIK3CD (0.56) | PER2PIK3CDHDAC1POLBCYP1A1 | |
| SCHEMBL22017741 | 0.82 | PIK3CD (0.46) | PER2PIK3CDCRY2HDAC1POLB | |
| SCHEMBL2602303 | 0.81 | PER2 (0.44) | PER2PIK3CDCRY2DPP4 | |
| SCHEMBL9815074 | 0.79 | PER2 (0.47) | PER2PIK3CDCRY2DPP4 | |
| SCHEMBL19872811 | 0.79 | PER2 (0.43) | PER2PIK3CDCRY2DPP4 | |
| SCHEMBL19364816 | 0.78 | PER2 (0.42) | PER2CRY2DPP4 | |
| SCHEMBL10150919 | 0.77 | PIK3CD (0.50) | PER2PIK3CDCRY2HDAC1POLB | |
| SCHEMBL11929087 | 0.77 | PIK3CD (0.48) | PER2PIK3CDCRY2HDAC1POLB | |
| SCHEMBL596921 | 0.77 | PER2 (0.38) | PER2PIK3CDCRY2 | |
| SCHEMBL8112323 | 0.76 | PER2 (0.41) | PER2CRY2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-06-08 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10017499-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8673954-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8507522-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8242156-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PER2 1914/4885PIK3CD 601/4885CRY2 4069/4885 |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PER2 1914/4885PIK3CD 601/4885CRY2 4069/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | PER2 1072/4885PIK3CD 739/4885CRY2 3570/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PER2 1914/4885PIK3CD 601/4885CRY2 4069/4885 |
| US-20100221215-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | PER2 1943/4885PIK3CD 736/4885CRY2 3914/4885 |
| US-10017499-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | PER2 1904/4885PIK3CD 828/4885CRY2 3842/4885 |
| US-20230331732-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PER2 3872/4885PIK3CD 2853/4885CRY2 4082/4885 |
| US-20230322771-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PER2 3872/4885PIK3CD 2853/4885CRY2 4082/4885 |
| US-20140193363-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PER2 1914/4885PIK3CD 601/4885CRY2 4069/4885 |
| US-20140341851-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | PER2 1914/4885PIK3CD 601/4885CRY2 4069/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | PER2 1904/4885PIK3CD 828/4885CRY2 3842/4885 |
| US-20230174565-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PER2 3888/4885PIK3CD 2786/4885CRY2 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.